Why the study?
Nuclear medicine has shown promise in diagnosing cancer therapy-related cardiomyopathies, heart failure, and peri- and myocarditis, but specific suggestions for applying available nuclear imaging techniques were needed.
Answers are grounded in this paper and cite their sources.
This EANM position paper outlines the role of nuclear medicine imaging, including ERNA and MPI, as valuable tools for assessing and monitoring cancer therapy-related cardiotoxicity.
Cardiotoxicity may present as (pulmonary) hypertension, acute and chronic coronary syndromes, venous thromboembolism, cardiomyopathies/heart failure, arrhythmia, valvular heart disease, peripheral arterial disease, and myocarditis. Many of these disease entities can be diagnosed by established cardiovascular diagnostic pathways. Nuclear medicine, however, has proven promising in the diagnosis of cardiomyopathies/heart failure, and peri- and myocarditis as well as arterial inflammation. This article first outlines the spectrum of cardiotoxic cancer therapies and the potential side effects. This will be complemented by the definition of cardiotoxicity using non-nuclear cardiovascular imaging (echocardiography, CMR) and biomarkers. Available nuclear imaging techniques are then presented and specific suggestions are made for their application and potential role in the diagnosis of cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Totzeck et al. (2022) conducted a review in Cancer therapy-related cardiotoxicity. Nuclear medicine imaging was evaluated. Nuclear medicine imaging techniques, including ERNA, SPECT, and PET, offer valuable and highly reproducible methods for the early detection and monitoring of cancer therapy-related cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: